BRIEF-Evaxion Reports 75% Objective Response Rate In Phase 2 Trial With Ai-Designed Personalized Cancer Vaccine EVX-01
Reuters
Oct 17
BRIEF-Evaxion Reports 75% Objective Response Rate In Phase 2 Trial With Ai-Designed Personalized Cancer Vaccine EVX-01
Oct 17 (Reuters) - Evaxion A/S EVAX.O:
EVAXION REPORTS 75% OBJECTIVE RESPONSE RATE IN PHASE 2 TRIAL WITH AI-DESIGNED PERSONALIZED CANCER VACCINE EVX-01
EVAXION A/S - 75% OBJECTIVE RESPONSE RATE AS 12 OUT OF 16 ADVANCED MELANOMA PATIENTS HAD OBJECTIVE CLINICAL RESPONSES
EVAXION A/S - IMMUNE ACTIVATION OBSERVED IN ALL PATIENTS WITH 81% OF EVX-01'S VACCINE TARGETS TRIGGERING A SPECIFIC RESPONSE
EVAXION A/S: TREATMENT WAS WELL TOLERATED IN PHASE 2 TRIAL
Source text: ID:nGNX47RTtC
Further company coverage: EVAX.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.